Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status approved; investigational
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 0074-1658; 0074-4637; 0074-9036; 0143-9624; 65162-823; 65862-936; 70121-1035; 43598-565; 55150-213; 67457-379; 66499-0019; 16729-311; 43598-562; 55150-215; 68382-331; 65862-938; 67457-692; 69452-147; 10888-8103; 10888-8104; 11014-0334; 48943-0033; 58032-1001; 68513-1054; 49483-689; 55150-212; 68382-330; 69452-145; 70121-1033; 70121-1034; 10888-8102; 14474-021; 0143-9625; 49483-687; 65862-937; 11014-0048; 55111-663; 70121-1036; 58272-192; 0074-9037; 43598-563; 49483-688; 55111-665; 63629-2452; 67457-380; 16729-310; 25000-017; 0143-9596; 55150-214; 63629-2453; 65162-822; 67457-389; 69452-146; 25000-014; 43598-564; 55111-664; 65162-824; 11014-0053; 25000-012
UNII 6702D36OG5
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Joint stiffness15.01.02.003--Not Available
Laboratory test abnormal13.18.01.001--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Loss of consciousness17.02.04.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mesenteric vascular insufficiency24.04.08.011; 07.15.02.010--Not Available
Mitral valve incompetence02.07.01.0020.001962%Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.0090.292350%
Myocardial ischaemia24.04.04.010; 02.02.02.0080.021583%Not Available
Myoclonus17.02.05.008--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Necrosis08.03.03.001; 24.04.02.0060.001962%Not Available
Neoplasm16.16.02.0010.007848%Not Available
Neoplasm malignant16.16.01.0010.016678%Not Available
Nephropathy20.05.03.0010.004905%Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
Ocular hyperaemia06.04.05.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.011--
Orthopnoea02.11.05.010; 22.02.01.020--Not Available
Osteoarthritis15.01.04.001--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene